BDRX Biodexa Pharmaceuticals plc
Listings ·
The exchange is expected on or about October 26, 2026. Holders must surrender eight old ADSs for one new one, and the release gives no reason for the change.
The change, aimed at Nasdaq's $1.00 minimum bid price, is expected on or about April 6, 2026. Holders must exchange five old ADRs for one new one, and the company says it cannot guarantee the change will work.
Biodexa priced 157,000 units and 2,891,781 pre-funded units at $3.28 each, with two Series L warrants per unit. The last reported sale price of the ADSs was $6.50 on December 16, 2025.
The best efforts sale would pair each ADS with a Series L warrant whose exercise price resets after issue. The company says it will likely receive no additional cash when those warrants are exercised.
Biodexa Pharmaceuticals plc is a clinical stage biopharmaceutical company developing products for the treatment or prevention of gastrointestinal cancers, including gastrointestinal stromal tumors (GIST) and familial adenomatous polyposis (FAP). It was originally formed in England and Wales in 2000 as Midatech Ltd, with a gold nanoparticle drug delivery platform. Its lead product, eRapa, is a proprietary formulation of rapamycin, an mTOR inhibitor, licensed in April 2024 from Rapamycin Holdings, Inc., d/b/a Emtora Biosciences, Inc. The Phase 3 study of eRapa in FAP is a double-blind, placebo-controlled trial in 168 patients, randomized 2:1 drug to placebo, conducted in approximately 30 clinical sites across the United States and Europe. As of March 16, 2026, there were 22 active clinical sites and 37 patients enrolled. The FDA granted fast track designation for eRapa on February 10, 2025. A Phase 2 study of eRapa in NMIBC is ongoing as an investigator-run trial at the University of Texas, San Antonio. On February 4, 2026, the company licensed MTX240, a molecular glue that it intends to develop initially for GIST, from Otsuka Pharmaceutical Co., Ltd.
| Product or program | What it is | Stage |
|---|---|---|
| eRapa | Proprietary rapamycin formulation for familial adenomatous polyposis and NMIBC | Phase 3 in FAP; Phase 2 in NMIBC |
| MTX240 | Molecular glue for gastrointestinal stromal tumors, licensed from Otsuka | Phase 1b/2a dose escalation planned after IND |
Our latest story on this, dated Dec 18, 2025: "Biodexa prices $10 million best-efforts offering of ADS units and warrants". The story links the filing or release it is based on. Read the story.
Biodexa Pharmaceuticals plc trades under the ticker BDRX on NASDAQ.
Biodexa Pharmaceuticals plc is listed on NASDAQ.
The SEC Central Index Key (CIK) for Biodexa Pharmaceuticals plc is 1643918. Its filings are on SEC EDGAR.
225,817,808,922 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-03-27.
Our directory records Biodexa Pharmaceuticals plc under United Kingdom.
Our directory classifies Biodexa Pharmaceuticals plc as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Biodexa Pharmaceuticals plc is US59564R8723.
aibio.space lists Biodexa Pharmaceuticals plc among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as X0.
Biodexa Pharmaceuticals plc is a clinical stage biopharmaceutical company developing products for the treatment or prevention of gastrointestinal cancers, including gastrointestinal stromal tumors (GIST) and familial adenomatous polyposis (FAP). It was originally formed in England and Wales in 2000 as Midatech Ltd, with a gold nanoparticle drug delivery platform.
eRapa: Proprietary rapamycin formulation for familial adenomatous polyposis and NMIBC Stage: Phase 3 in FAP; Phase 2 in NMIBC.
MTX240: Molecular glue for gastrointestinal stromal tumors, licensed from Otsuka Stage: Phase 1b/2a dose escalation planned after IND.
Our latest story on Biodexa Pharmaceuticals, dated Oct 8, 2026: "Biodexa changes ADS ratio to 400 ordinary shares, a one-for-eight reverse ADS split". The exchange is expected on or about October 26, 2026. Holders must surrender eight old ADSs for one new one, and the release gives no reason for the change. Source.
From our story of Dec 18, 2025: The auditor's report on the 2024 financial statements, from PKF Littlejohn LLP, contains an explanatory paragraph about the company's ability to continue as a going concern. Source.
Reported a reverse stock split. SEC Form 6-K. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Filed a registration statement for a share offering. SEC Form F-1. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio